Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease by Put, N.M.J. van der et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24871
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Q J Med 1997; 90:511-517
Sequence analysis of the coding region of human methionine 
synthase: relevance to hyperhomocysteinaemia in 
neural-tube defects and vascular disease
N.M.J. VAN DER PUT, E.F. VAN d er  MOLEN, L.A.J. KLUIJTMANS, S.G. HEIL, 
J.M.F, TRIJBELS, T.K.A.B. ESKES1, D. VAN OPPENRAAIJ-EMMERZAAL, 
R. BANERJEE2 and H.J. BLOM
From the Departments o f Pediatrics a n d 1 Gynaecology & Obstetrics, University Hospital 
Nijmegen, The Netherlands, and2Department o f Biochemistry, University of Nebraska,
Lincoln> USA
Received 19 March 1997 and in revised form 10 June 1997
Summary
Elevated homocysteine (Hey) levels are observed in 
two apparently unrelated diseases: neural-tube 
defects (NTD) and premature vascular disease. 
Defective human methionine synthase (MS) could 
result in elevated Hey levels. We sequenced the 
coding region of MS in 8 hyperhomocysteinaemic 
patients (4 NTD patients and 4 patients with preg­
nancies complicated by spiral arterial disease, SAD). 
We identified only one mutation resulting in an 
amino acid substitution: an A—>G transition at bp 
2756, converting an aspartic acid (D919) into a 
glycine (C). We screened genomic DNA for the 
presence of this mutation in 56 NTD patients, 69
mothers of children with NTD, 108 SAD patients 
and 364 controls. There was no increased preval­
ence of the G G and AG genotypes in NTD patients, 
their mothers or SAD patients. The D919G mutation 
does not seem to be a risk factor for NTD or vascular 
disease. We then examined the mean Hey levels for 
each MS genotype. There was no correlation 
between GG- or AG-genotype and Hey levels. The 
D919G mutation is thus a fairly prevalent, and prob­
ably benign polymorphism. This study, though lim­
ited, provides no evidence for a major involvement 
of MS in the aetiology of homocysteine-related dis­
eases such as NTD or vascular disease.
Introduction
Two apparently unrelated diseases, neural-tube 
defects (NTDs) and premature vascular disease, are 
both associated with moderately elevated homocyst­
eine (Hey) levels.1'3 Enzymes and cofactors involved 
in Hey metabolism are currently being investigated 
for their contribution to these diseases. Hey is a 
braneh-point metabolite of methionine metabolism, 
and can be remethylated to methionine or catabol- 
ized in the transsulphuration pathway to cysteine, 
(Figure 1).
NTDs account for a significant part of present-day 
perinatal morbidity and mortality. Several studies 
showed that perieonceptional folate administration
reduces the occurrence and recurrence risk of 
NTDs.4'5 We have postulated that heterozygosity for 
cystathionine /?-synthase (CS) deficiency could be a 
cause of moderate hyperhomocysteinaemia in NTD, 
but we have not found evidence for a defective CS 
in mothers of children with NTD.1
5,1O-Methylenetetrahydrofolate reductase
(MTHFR) is one of the key enzymes in the folate- 
dependent remethylation of Hey to methionine. We 
recently showed that homozygosity for the 677C-*T 
mutation in the MTHFR gene, causing thermolability 
of the enzyme,6“8 can partly explain the observed 
elevated Hey levels in NTD, and this has recently
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Figure 1. A simplified scheme of folate-dependent homocysteine metabolism. Key enzymes are given. MS, methionine 
synthase; MTHFR, 5,10-methy I en etetra hydrofolate reductase; MTHFD, 5,1O-methylenetetrahydrofolate dehydrogenase; 
SHMT, serine hydroxymethyl transferase; CBS, cystathionine ^-synthase.
been confirmed by others.9,10 The 677C->T mutation 
in the MTHFR gene is the first identified genetic risk 
factor for NTD. However, even after exclusion of 
individuals homozygous for the 677C-*T mutation 
in MTHFR, we still observe significantly elevated 
Hey levels in NTD patients and their parents.11 So, 
in addition to the 677C->T mutation in MTHFR, 
other mutations in genes affecting the conversion of 
Hey to methionine could be present in these families.
In most Western countries, vascular disease is one 
of the main causes of death. Along with high blood 
pressure and cholesterol, increased plasma Hey level 
is a risk factor for vascular disease, with a relative 
risk comparable to hypercholesterolaemia.3 It has 
been postulated that the elevation of Hey levels in 
patients with vascular disease could be caused by 
heterozygosity for CS.12,13 However, we have not 
found any evidence for involvement of CS deficiency 
in vascular disease,14 The 677C-^T mutation in the 
MTHFR gene, resulting in elevated Hey levels, can 
only partly explain the elevated Hey levels in patients 
with vascular disease.14 Several studies have reported 
that folate administration reduces Hey concentrations 
of hyperhomocysteinaemic patients with vascular 
disease.15,16 Therefore, a defective function of other 
folate-dependent enzymes may be involved in hyper­
homocysteinaemia of vascular patients. However, 
the clinical benefits of this Hcy-Iowering therapy are 
unproven.
The remethylation of Hey occurs by transfer 
of a methyl group from 5-methyItetrahydrofoIate 
(Me-THF) via cobalamin to Hey. This reaction is 
catalysed by 5-methyltetrahydrofolate homocysteine 
methyltransferase (methionine synthase), which is 
probably present in all mammalian tissues, and
requires cobalamin as a cofactor. The enzyme, 
betaine-homocysteine methyltransferase, can also 
remethylate Hey to methionine, but this enzyme is 
present only in the liver. Several studies have 
suggested that a defective methionine synthase 
(MS) could be a critical defect in folate-related 
NTDs.1'2'17,18 MS is essential for maintaining adequate 
intracellular methionine and tetrahydrofoiate pools, 
as well as for ensuring that the Hey concentration 
does not reach toxic levels. Since elevated Hey 
levels are observed not only in NTD patients and 
their parents, but also in patients with vascular 
diseases, both diseases could be caused by defect­
ive MS.
Recently, the human MS cDNA-sequence has 
been cloned19'20 and mutations causing the inborn 
error of metabolism cbIC have been described.20, 21 
The gene has been mapped to 1q43, near the 
telomere of chromosome 1, The human MS gene 
has an open reading frame of 3768 bases which 
encodes a protein of 1256 amino acids with a 55% 
homology compared to E. coli MS. Although enzymic 
studies have indicated a higher activity for MS in 
kidney, the RNA expression levels of MS seem to be 
similar in different tissues.19
In order to study the postulated involvement of 
MS at the genomic level, we selected eight patients 
with mild hyperhomocysteinaemia: four NTD 
patients and four women with severe spiral arterial 
disease (SAD) during their pregnancies. SAD causes 
infarction of the placenta, resulting in a stillborn or 
severely growth-retarded child, and is predominantly 
the result of spiral artery occlusion in the myome­
trium or decidua. Histological examination of the 
spiral arteries in SAD reveals one or more signs of
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vascülopathy, i.e. arteriosclerosis, narrowing, nec­
rosis and thrombosis. SAD is an occlusive arterial 
disease that is associated with elevated Hey levels,22 
like most vascular diseases. By direct sequencing of 
the complete coding region of MS from eight hyper­
homocysteinaemic patients, we examined whether 
mutations in the MS gene were involved in these 
Hcy-related diseases.
Methods
Patients
Eight patients with mild hyperhomocysteinaemia 
(Hey levels above the normal range for their sex and 
age category),1 four NTD patients and four vascular 
patients who had a pregnancy complicated by SAD, 
were selected for direct sequencing of the cDNA of 
the MS gene. The elevated Hey levels were not due 
to the TT genotype for the 677C—>T transition in 
MTHFR, except patient SAD 4, who had a TT 
genotype but had very high Hey levels. The age, 
sex, folate and Hey data of these individuals are 
given in Table 1. The normal ranges of plasma folate, 
red-cell folate and Hey are between 6-22 nmol/l; 
213-817 nmol/l and 4.6-15 jumol/l, respectively.1
To examine whether the 2756A—»G mutation was 
associated with mild hyperhomocysteinaemia, or was 
a genetic risk factor for NTD or SAD, we studied 
the prevalence of this mutation among NTD 
patients and mothers with NTD-affected offspring, 
and patients who had suffered from SAD. The study 
group consisted of 69 mothers with a child with 
NTD (mean age 46, SD 12.6 years) and 56 NTD 
patients, mostly spina bifida, (mean age 21, SD 12.3 
years).6-0 Furthermore, we studied 108 patients with 
SAD (mean age 34, SD 5.3 years). The diagnosis of 
SAD was established if the placenta was character­
ized by circumscribed areas of villous necrosis 
combined with a stillborn fetus or a severely growth- 
retarded child, i.e. having a birth weight below the 
10th percentile of gestational age. The population-
based control group consisted of 364 unrelated 
Dutch individuals of either gender and no history of 
NTD or SAD (mean age 51, SD 12.4 years).0
Laboratory methods
Total homocysteine concentrations were measured 
in EDTA plasma.23
Total RNA of NTD patients was extracted from 
EBV (Epstein Barr Virus) cell lines and the RNA of 
the vascular patients from lymphocytes isolated of 
whole blood,24 and was stored as an ethanol precipit­
ate at — 80°C. A 5 jag sample of RNA was reverse- 
transcribed to cDNA in 1 h at 42°C with 200 units of 
Superscript!! reverse transcriptase (Life Technologies), 
using oligo(dT) and random hexanucleotides. A 
2.5 )_lI aliquot of this first-strand cDNA was amplified 
by PCR. Amplifications were carried out in a total 
volume of 100 jul, containing 100 ng forward and 
reverse primer, 200 |iM each dNTP, 10 mM Tris-HCl 
(pH 8.3), 50 mM KCI, 0.75-1.5 mM MgCl2 and
1 unit Taq polymerase (Life Technologies). 
Amplification parameters were as follows: 35 cycles 
of 92 °C/60 s (dénaturation), 54-64 °C/60 s 
(annealing) and 72°C/90 s (extension). The cycles 
were preceded by an initial dénaturation step of 2 
min at 92 °C and were followed by a final extension 
of 7 min at 72 °C.
PCR and sequencing primers were designed based 
on the cDNA sequence.19 W e constructed 6 pairs of 
oligonucleotides (MS1-12), (Table 2). These primers 
were designed to generate overlapping fragments of 
700-900 bp, covering the total cDNA sequence. 
These fragments were screened for the presence of 
mutations by direct sequencing; two forward and 
two reverse oligonucleotides were used to analyse 
each of the six fragments.
The sequence analysis was performed by auto­
mated sequencing (ABI Prism, model 377 version 
2.1.2), using the ABI Prism Taq DyeDeoxy terminator 
cycle sequencing ready reaction kit (Perkin Elmer), 
according to the instructions of the manufacturer.
Table 1 Patient profiles: sex, age, folate and fasting Hey levels of the selected hyperhomocysteinaemic study group
Patient Sex Age (years) PF (nmol/l) RCF (nmol/l) Hcy (nmol/l)
NTD 1 M 23 14.0 580 16.5
NTD 2 F 14 8.6 390 15.2
NTD 3 F 30 7.3 350 21.0
NTD 4 F 17 13.0 350 23.3
SAD 1 F 34 16.0 470 15.8
SAD 2 F 34 18.0 470 20.9
SAD 3 F 31 13.0 420 27.8
SAD 4 F 32 6.0 440 57.3
Hey, homocysteine; PF, plasma folate; RCF, red-cell folate.
Table 2 Oligonucleotide primers used for PCR and sequencing of the MS gene of hyperhomocysteinaemic patients
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Name Sequence Location
MS1F 5'GCGTGTCTGGCTGCTAGGC —*283 to —265
MS1BF 5 'CCGTCGTCACCTGTGG AGAGC -47 to -67
MS2R 5 'GTGATGTTCCTATAATCCGGCC 503-482
MS3F 5'AGUI I rGTGGCAGGGGCTC 418-436
MS4R 5'GCTCCCAI I ICCACCTGCAC 1229-1210
MS5F 5TTGCAGAGCGCTGTAATGTTGC 1121-1142
MS6R 5 AGTG GCCTCAG G GTCTTTATTCC 1929-1907
MS7F 5'AGTCTGGCATGGACATGGGG 1811-1830
MS8R 5'CAGGTGCACTGTATCTCGGAGC 2638-2617
MS9F 5 'G ACT CAT C ACT CCTT CCCT G G 2492-2512
MSI OR 5 'AACA G G CCCAG GTAGTCACG 3299-3280
MS11F 5'AGGCAACAGGCTGACAAGGAC 3196-3216
MS12R 5 'CAGGTAAGT GTCAGCCAG ATGC 3912-3891
MS13F 5'ATTCTGCACAAGACGATTATGGTG 73-96
MS14R 5 'GT CCCC AT CCCTCC AT CCAG 116-97
MS15F 5 'CACT CTACATTGG ATTAAATT GTGC 758-782
MS16R 5 'CATTGGGATAACAGAGGACATAGGC 862-838
MS17F 5 'G AT G A AG AAG G AC AG GCA ACAG 1501-1522
MS18R 5'TTTGTGTCTGTTTCTGTTGCCTG 1535-1513
MS19F 5 'CCTCAGGTTATAAAGTCAGCCCG 2191-2213
MS20R 5 'AT GAAAGG AATAAGGTGGCCAAC 2252-2230
MS21F 5 TTG AAGACTATGACCTGCAGAAGC 2882-2905
MS22R 5'GU ICCAGTCAATGTAGTCCACC 2929-2907
MS23F 5 ACC ATG TG G AG ACTCG C AG AC 3562-3582
MS24R 5'TGGTGAGCTTCTCGGTGTGG 3565-3546
MS28F 5'GGTGTGTTCCCAGCTGTTAGATG 2673-2695
MS29R 5'GAGGTTCAGACAGCCAATCC 2845-2826
MS30R 5 'G AC ACT G A AG ACCT CT G AI I IGAAC (intronic)
Numbering starts at the ATG-site as in Leclerc et al.20
DNA was isolated from whole blood and lympho­
cytes as described by Miller et a i25 and approxi­
mately 100 ng was used for PCR amplification. When 
we tried to confirm the 2756A^C mutation on 
genomic DNA, we observed that a large intron of 
over a 1000 bp was present in the genomic DNA at 
position 2775 of the cDNA. We sequenced the 
intron with the oligonucleotides MS28 and MS29 
and selected an intronic oligonucleotide (MS30), 
(Table 2), to make screening for the 2756A-^G 
mutation on genomic DNA possible. The PCR for 
detection of this mutation on genomic DNA was 
carried out in a total volume of 50 jil, containing 
50 ng of the MS28 and MS30 oligonucleotides (see 
Table 2), 200 (iM of each dNTP, 10mM Tris-HCI 
(pH 8.3), 50 mM KCI, 1.0 mM MgCl2 and '! unit Taq 
polymerase (Life Technologies). PCR parameters were 
as follows: an initial dénaturation step of 2 min at 
92 °C, followed by 35 cycles of: 92 °C/60 s (dénatura­
tion), 56°C/60 s (annealing) and 72 °C/90 s (exten­
sion), and a final extension for 7 min at 72 °C  The 
amplified PCR fragments were digested with the 
restriction enzyme Haelll to screen for the presence 
of the2756A-+G mutation. An A A genotype resulted 
in an uncut fragment of 265 bp, whereas an AG
genotype gave three fragments of 265, 180 and 
85 bp, and a GG genotype showed two fragments 
of 180 and 85 bp.
Statistics
Odds ratios (OR) and 95% Cls for the 2756A-»G 
mutation were calculated to estimate the relative risk 
of this mutation in NTD patients, their mothers and 
SAD patients. The Hey concentrations per MS geno­
type were expressed as means+ SD. Statistical signi­
ficance was tested by a paired Wilcoxon Rank Sum 
test p < 0*05 was considered statistically significant, 
all p values were two-tailed.
Results
The human MS gene was examined for involvement 
in mild hyperhomocysteinaemia observed in NTD 
and vascular diseases. To look for mutations in the 
coding region of MS, MS cDNA from 4 NTD patients 
and 4 patients with SAD with mildly elevated Hey 
levels, was screened by direct sequencing.
Total RNA of NTD patients was extracted from 
EBV cell lines, and that of the vascular patients from
Hey levels in NTD and premature vaseuiar disease 515
isolated lymphocytes. The isolated RNA was reverse- 
transcribed to cDNA and amplified by PCR for direct 
sequencing analysis. RT-PCR of total lymphoblastoid 
and lymphocyte RNA yielded products of the 
expected size, indicating that MS is expressed in 
cultured lymphoblasts and lymphocytes.
By direct sequencing of the entire coding region of 
MS of the selected patients with mild hyperhomocyste­
inaemia, we observed three silent mutations in the 
cDNA of these individuals, see Table 3. Furthermore, 
we identified an A->G transition at bp 2756, con­
verting an aspartic acid into a glycine (D919G). This 
mutation was present in two SAD patients and one 
NTD patient, in a heterozygous state in all. The 
observed nucleotide substitution creates a Haelll 
restriction site, which allowed the confirmation of the 
D919G mutation on genomic DNA.
To determine whether the 2756A-+G mutation 
was a risk factor for NTD offspring and vascular 
disease, we screened for its prevalence in the gen­
omic DNA of 56 NTD patients, 69 mothers of 
children with NTDs, 108 SAD patients and 364 
Dutch controls. After amplification of the appropriate 
region of the genomic DNA by a PCR reaction using 
primers MS28 and MS30, the PCR fragment was 
digested with Haelll. The homozygous mutated GG 
genotype was present in only 1.8% of the NTD 
patients, 2.9% of their mothers, 2.8% of the SAD 
patients and 3.3% of the controls. Table 4 shows 
that the AG-genotype was fairly prevalent, that is in 
25% of the NTD patients, 27.5% of the mothers 
with NTD-affected offspring, 28.7% of the SAD 
patients and 25.8% of the controls. The frequency 
in the control group of the A-allele is 0.84 and of 
the G-allele 0.16. According to the Hardy-Weinberg 
equation the following genotype distribution was 
expected, AA genotype 70,6%; AG genotype 26.9% 
and GG genotype 2.6%, which is in agreement with 
the observed genotype distributions among the differ­
ent study populations, see Table 4.
There was at most only a slightly increased 
prevalence of the GG and AG genotypes in NTD 
patients, their mothers, and SAD patients, indicating 
that this amino acid change is not a major (if any) 
risk factor for NTD or SAD. This is reflected in the 
calculated ORs of 0.5-1.1 for the GG and AG 
genotypes in SAD patients, NTD patients and their 
mothers (Table 5).
Table 4 Prevalence of the 2756A->G mutation in the 
MS gene of controls, SAD patients, NTD patients and 
their mothers
n Genotype (%)
AA AG GG
Controls 
SAD patients 
NTD patients 
NTD mothers
364 70.9 
108 68.5 
56 73.2 
69 69.6
25.8
28.7
25.0
27.5
3.3
2.8
1.8
2.9
Table 5 Calculated odds ratios (OR) and 95% CIs for 
the GG and AG genotype vs. the AA genotype of MS for 
SAD patients, NTD patients and their mothers
GG genotype AG genotype
OR 95% Cl OR 95% Cl
SAD patients 
NTD patients 
NTD mothers
0.9 [0.3-4.0] 
0.5 [0.1-4.0] 
0.9 [0.2-3,9]
1.1
1.0
1.1
[0.8-1.6] 
[0.6—1.6] 
[0.7-1.6]
To examine whether the 2756A-+G mutation in 
MS was associated with mild hyperhomocysteinae­
mia, we determined the mean Hey levels of the 
different MS genotypes. The Hey levels of mothers 
with a NTD child with an AG genotype were 
elevated when compared with the Hey levels of 
mothers with an AA or GG genotype, but not 
significantly so. The Hey levels of NTD patients, 
patients with SAD and controls between the three 
MS genotypes did not differ, see Table 6.
Discussion
By direct sequence analysis of the complete coding 
region of MS we observed four mutations (Table 3). 
Three were silent mutations, and only one mutation, 
an A~*G substitution at bp 2756, resulted in an 
amino acid change, of an aspartic acid into a glycine 
(D919G). D919 corresponds to Q893 in E  co li MS. 
This is at the penultimate position in a long helix 
that leads out of the cobalamin domain to the 
S-adenosylmethionine-binding domain in the highly
Table 3 Sequence differences found in the coding region of the MS gene of eight patients with mild hyperhomocysteinaemia
Mutation Location Amino acid substitution
Silent
Polymorphism
2053A—*T 
2127A—>G 
3144A—>G 
2756A-+G
Lysine (685)—Hysine 
Glutamate (709)->-giutamate 
Alanine (1048)—>alanine 
Aspartic acid (D919)—>glycine (G)
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Table 6 Relationship between MS genotype and plasma 
homocysteine levels in Dutch controls/ SAD patients, 
NTD patients and their mothers
n Genotype
AA AG GG
Controls 364 13.5 13.0 12.4
(±4.5) (±5.6) (±2.1)
SAD patients 108 13.9 13.6 11.9
(±5.1) (±4.6) (±2.7)
NTD patients 56 13.3 12.4 15.5
(±3.7) ( ±3.2) (NP)
NTD mothers 69 12.8 15.1 12.4
(±2.9) (±11.2) (±0.3)
Plasma homocysteine concentrations are expressed as 
means ±SD, in jimol/l. NP, not possible, because n= l.
homologous bacterial MS.26 Having the glycine res­
idue at this position, which is a strong helix breaker, 
versus aspartic acid which is a moderate helix maker, 
could have an effect on the secondary structure of 
the protein and therefore have functional con­
sequences. This 2756A->G transition has also been 
observed in cblG patients and controls in the study 
of Leclerc et a i20
A possible involvement of the D919G mutation 
in the risk for NTD and SAD was investigated by 
analysing the prevalence of the 2756A-»G mutation 
in the MS gene of NTD patients, mothers with 
NTD-affected offspring and patients that had suffered 
from SAD during their pregnancy. No significantly 
increased prevalence of GG and AG genotypes 
was present in NTD patients, their mothers or SAD 
patients when compared with the prevalence among 
controls, resulting in ORs of 0.5-1.1 for NTD 
patients, their mothers and patients with SAD (Tables 
4 and 5), indicating that this amino acid change is 
not a major (if any) risk factor for NTD or SAD. The 
presence of the D919G mutation has also no effect 
on the Hey levels (Table 4). This suggests that the 
D919G mutation in the MS gene is a fairly prevalent, 
but probably benign polymorphism. Expression stud­
ies with the D919G mutation will resolve whether 
this polymorphism has a significant effect on MS 
function, as might have been expected from its 
postulated effect on helix formation.
The folate levels of mothers with NTD offspring 
are not deficient,11 suggesting that there are no major 
nutritional folate deficiencies. The 677C-VT mutation 
in the MTHFR gene can explain at most 27.4% of 
the protective effect of folate.7 Since folate adminis­
tration reduces the risk for NTD by at least 70% or 
more,4,5 this implies that there may be other genetic 
defects present in the folate-related Hey metabolism 
that can be corrected by an additional folate intake.
In order to identify these candidate defective 
enzymes in the folate-dependent Hey metabolic 
pathway, we recently analysed the plasma cobala­
min, plasma and red cell folate, and plasma homo­
cysteine levels of NTD patients and their parents.11 
We observed, even after exclusion of those indi­
viduals homozygous for the 677C-»T mutation in 
the MTHFR gene, significantly elevated Hey levels 
and decreased plasma folate levels in NTD patients 
and their parents. Plasma folate is mostly (80-90%) 
Me-THF, which is the circulating form of folate. 
Thus, a defective MS would not lead to decreased 
plasma folate levels, but rather increased plasma 
folate concentrations, since Me-THF is the substrate 
of MS in the remethylation of Hey to methionine. 
So, the results of our vitamin and Hey analyses of 
our NTD population11 are in agreement with the 
present sequencing results. Neither indicate a direct 
or significant role for MS in the aetiology of NTD. It 
is possible that other mutations in MS may have 
been missed, since we screened MS in only eight 
hyperhomocysteinaemic patients by direct sequen­
cing, However, if such mutations exist, they are 
unlikely to be present at high enough frequency to 
explain a significant proportion of the observed 
hyperhomocysteinaemia among NTD and vascular 
disease patients.
Since, the elevated Hey levels in patients with 
vascular disease, mothers of children with NTDs, or 
NTD patients, are probably not due to a decreased 
function of CS or MS, and only partly due to the 
677C-*T mutation in the MTHFR gene, other 
enzymes involved in the folate-dependent Hey meta­
bolism may be compromised. In our vitamin study, 
we observed significantly decreased plasma folate 
levels in NTD families.11 Decreased Me-THF levels 
have also been reported in patients with vascular 
disease,27,28 suggesting the presence of other muta­
tions present in MTHFR or other enzymes in the 
folate metabolism involved in the synthesis of 
Me-THF. Such candidate enzymes (see Figure 1), 
leading to mild hyperhomocysteinaemia in NTD and 
vascular disease, include serine hydroxymethyl- 
transferase, methylenetetrahydrofolate dehydro­
genase and the auxiliary redox proteins that regulate 
methionine synthase or MTHFR.
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